Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 9/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 9/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.36 |
| ▸ | CDK9 | P50750 | 8/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.36 |
| ▸ | CDK2 | P24941 | 7/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.34 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799233 | 0.87 | CCNT1 (0.36) | ROCK1CDC42BPBCCNT1CDK9CDK5 | |
| SCHEMBL1799953 | 0.79 | ROCK1 (0.43) | ROCK1CDC42BPBCCNT1CDK9CDK5 | |
| SCHEMBL2753851 | 0.74 | ROCK2 (0.55) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672634 | 0.73 | CDK9 (0.58) | ROCK1CDC42BPBCCNT1CDK9CDK5 | |
| SCHEMBL1801778 | 0.72 | BRD4 (0.44) | RAB9ASMN1; SMN2 | |
| SCHEMBL1796417 | 0.65 | JAK3 (0.43) | ROCK1CDK9CDK5ROCK2JAK2 | |
| SCHEMBL1802880 | 0.63 | CDK1 (0.39) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27835141 | 0.63 | CDK5 (0.61) | ROCK1CDC42BPBCCNT1CDK9CDK5 | |
| SCHEMBL24673121 | 0.63 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL12257978 | 0.61 | NUDT1 (0.56) | ROCK1CDK9CDK5ROCK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | ROCK1 398/4885CDC42BPB 153/4885CCNT1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.